| Primary |
| Acute Lymphocytic Leukaemia |
31.0% |
| Non-hodgkin's Lymphoma |
19.5% |
| Diffuse Large B-cell Lymphoma |
8.1% |
| B-cell Lymphoma |
6.9% |
| Lymphoma |
6.2% |
| Hodgkin's Disease |
4.0% |
| Product Used For Unknown Indication |
3.4% |
| Ewing's Sarcoma |
3.2% |
| Chronic Lymphocytic Leukaemia |
2.2% |
| Multiple Myeloma |
2.0% |
| B Precursor Type Acute Leukaemia |
1.9% |
| Neoplasm Malignant |
1.5% |
| Non-hodgkin's Lymphoma Stage Iii |
1.5% |
| Lymphocytic Leukaemia |
1.4% |
| Diffuse Large B-cell Lymphoma Stage Iii |
1.3% |
| T-cell Type Acute Leukaemia |
1.3% |
| Burkitt's Lymphoma |
1.2% |
| Burkitt's Lymphoma Stage Iii |
1.2% |
| Peripheral T-cell Lymphoma Unspecified |
1.1% |
| Acute Myeloid Leukaemia |
1.0% |
|
| Stem Cell Transplant |
15.7% |
| Sepsis |
9.1% |
| Cytogenetic Abnormality |
8.7% |
| Leukoencephalopathy |
7.0% |
| Neutropenia |
6.5% |
| Thrombocytopenia |
6.1% |
| Reversible Posterior Leukoencephalopathy Syndrome |
4.8% |
| Encephalopathy |
4.3% |
| Febrile Neutropenia |
4.3% |
| Neuropathy Peripheral |
3.9% |
| Pancytopenia |
3.9% |
| Pyrexia |
3.9% |
| Posterior Reversible Encephalopathy Syndrome |
3.5% |
| Pulmonary Embolism |
3.0% |
| Septic Shock |
3.0% |
| Staphylococcal Infection |
3.0% |
| Acute Myeloid Leukaemia |
2.6% |
| Neurotoxicity |
2.2% |
| Progressive Multifocal Leukoencephalopathy |
2.2% |
| Respiratory Failure |
2.2% |
|
| Secondary |
| Diffuse Large B-cell Lymphoma |
28.1% |
| Acute Lymphocytic Leukaemia |
12.0% |
| Drug Use For Unknown Indication |
9.2% |
| B-cell Lymphoma |
8.0% |
| Non-hodgkin's Lymphoma |
7.4% |
| Product Used For Unknown Indication |
7.0% |
| Hodgkin's Disease |
4.9% |
| Mantle Cell Lymphoma |
3.7% |
| Burkitt's Lymphoma |
3.7% |
| Prophylaxis |
2.7% |
| Lymphoma |
2.6% |
| Peripheral T-cell Lymphoma Unspecified |
1.6% |
| T-cell Lymphoma |
1.5% |
| Sarcoma |
1.4% |
| Rhabdomyosarcoma |
1.1% |
| Ewing's Sarcoma |
1.1% |
| Chemotherapy |
1.1% |
| Chronic Lymphocytic Leukaemia |
1.0% |
| Multiple Myeloma |
1.0% |
| Burkitt's Leukaemia |
0.9% |
|
| Febrile Neutropenia |
15.9% |
| Death |
7.0% |
| Neutropenia |
6.9% |
| Sepsis |
6.7% |
| Thrombocytopenia |
6.3% |
| Infection |
5.8% |
| Pyrexia |
5.3% |
| Pneumonia |
5.1% |
| Vomiting |
4.7% |
| Off Label Use |
4.3% |
| White Blood Cell Count Decreased |
4.2% |
| Toxicity To Various Agents |
4.1% |
| Myelodysplastic Syndrome |
3.8% |
| Pneumocystis Jiroveci Pneumonia |
3.7% |
| Pulmonary Embolism |
3.2% |
| Weight Decreased |
2.9% |
| Septic Shock |
2.7% |
| Respiratory Failure |
2.6% |
| Thrombosis |
2.5% |
| Hepatitis B |
2.4% |
|
| Concomitant |
| Drug Use For Unknown Indication |
13.7% |
| Diffuse Large B-cell Lymphoma |
12.3% |
| Non-hodgkin's Lymphoma |
11.1% |
| Acute Lymphocytic Leukaemia |
9.6% |
| Product Used For Unknown Indication |
9.2% |
| B-cell Lymphoma |
8.1% |
| Multiple Myeloma |
7.4% |
| Lymphoma |
6.9% |
| Chemotherapy |
5.2% |
| Prophylaxis |
2.9% |
| Chronic Lymphocytic Leukaemia |
2.0% |
| Idiopathic Thrombocytopenic Purpura |
1.9% |
| Mantle Cell Lymphoma |
1.7% |
| Pain |
1.6% |
| Hypertension |
1.3% |
| Hodgkin's Disease |
1.3% |
| Burkitt's Lymphoma |
1.2% |
| Premedication |
0.9% |
| T-cell Lymphoma |
0.9% |
| Malignant Lymphoid Neoplasm |
0.7% |
|
| Vomiting |
9.4% |
| Progressive Multifocal Leukoencephalopathy |
8.3% |
| Febrile Neutropenia |
8.1% |
| Sepsis |
7.8% |
| Thrombocytopenia |
6.6% |
| Weight Decreased |
6.5% |
| Pyrexia |
6.3% |
| White Blood Cell Count Decreased |
5.8% |
| Death |
5.7% |
| Neutropenia |
5.7% |
| Pneumocystis Jiroveci Pneumonia |
4.0% |
| Respiratory Failure |
3.9% |
| Wound Drainage |
3.6% |
| Renal Failure |
3.4% |
| Septic Shock |
3.0% |
| White Blood Cell Count Increased |
2.6% |
| Pneumonia |
2.5% |
| Pleural Effusion |
2.4% |
| Pulmonary Fibrosis |
2.3% |
| Drug Ineffective |
2.3% |
|
| Interacting |
| Acute Lymphocytic Leukaemia |
16.9% |
| Non-hodgkin's Lymphoma Unspecified Histology Aggressive |
11.7% |
| Non-hodgkin's Lymphoma |
9.8% |
| Ewing's Sarcoma |
9.1% |
| Product Used For Unknown Indication |
8.5% |
| Diffuse Large B-cell Lymphoma |
7.2% |
| Prophylaxis |
6.8% |
| B-cell Lymphoma |
4.6% |
| Drug Use For Unknown Indication |
3.3% |
| Lymphoma |
3.3% |
| Bone Sarcoma |
2.9% |
| Retinoblastoma |
2.6% |
| Febrile Neutropenia |
2.3% |
| Brain Neoplasm |
2.0% |
| Fungal Infection |
2.0% |
| Burkitt's Lymphoma |
1.6% |
| Chronic Lymphocytic Leukaemia |
1.6% |
| Gastritis |
1.3% |
| Oral Candidiasis |
1.3% |
| Precursor T-lymphoblastic Lymphoma/leukaemia |
1.3% |
|
| Drug Interaction |
31.8% |
| Neuropathy Peripheral |
14.1% |
| Ileus Paralytic |
10.6% |
| Neurotoxicity |
10.6% |
| Muscular Weakness |
4.7% |
| Renal Impairment |
3.5% |
| Agranulocytosis |
2.4% |
| Apnoea |
2.4% |
| Autonomic Neuropathy |
2.4% |
| Leukopenia |
2.4% |
| Neutropenia |
2.4% |
| Ocular Vascular Disorder |
2.4% |
| Weight Decreased |
2.4% |
| Anaphylactic Reaction |
1.2% |
| Angioedema |
1.2% |
| Bladder Cancer |
1.2% |
| Constipation |
1.2% |
| Fat Embolism |
1.2% |
| Hyponatraemia |
1.2% |
| Ileus |
1.2% |
|
